Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 11 to 20 of 766

TitleReference numberPublishedLast updated
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Ranibizumab for treating choroidal neovascularisation associated with pathological myopiaTA298
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283
Ranibizumab and pegaptanib for the treatment of age-related macular degenerationTA155
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underTA975
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Atogepant for preventing migraineTA973
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971

Results per page

  1. 10
  2. 25
  3. 50
  4. All